Mr. Ashok Kumar Windlass appointed as Founder President (Senior Management Personnel) effective from November…
As filed · Mr. Ashok Kumar Windlass appointed as Founder President (Senior Management Personnel) effective from November 6, 2026
RoutineLowmateriality 26 out of 100
What happened
FactMr. Ashok Kumar Windlass appointed as Founder President (Senior Management Personnel) effective from November 6, 2026. A copy of the said Financial Results together with the Limited Review Report issued by M/s J C Bhalla.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Capex
WithdrawnEarlierQ1 FY27
We are on track for the commercialization of Plant-6 in H1 FY27, which will further strengthen our manufacturing capacity and enable us to support future growth opportunities.
NowQ1 FY27
Our Injectables and Plant-2 Extension facilities continue to drive scalable growth, highlighting the effectiveness of our strategic investments.
Change
FactGuidance withdrawn
Implication
CapitSignal interpretationThe earlier statement mentioned the commercialization of Plant-6 in H1 FY27, but the current statement does not mention Plant-6 at all.confidence 90%
Watch next
Fact- We are on track for the commercialization of Plant-6 in H1 FY27, which will further strengthen our manufacturi (management committed by H1 FY27)
Evidence
- Windlas Biotech Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.(opens the original filing in a new tab)
- Earlier statement · Q1 FY27
- Latest statement · Q1 FY27
How CapitSignal classified this
- Reasoning:
- DIRECTOR_CHANGE base 26; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%